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A synthetic peptide modeled after the calmodulin 
(CaM)-binding domain of rabbit skeletal muscle 
myosin light chain kinase, Lys-Arg-Arg-Trp-Lys5- 
Lys-A sn-Phe-Ile-A la10-V al-Ser-A la-A la-A sn15-Arg- 
Phe-Glycyl amide (M5), inhibited the CaM-independ­
ent chymotryptic fragment o f the enzyme, C35 (Edel­
man, A. M., Takio, K., Blumenthal, D. K., Hansen, R. 
S., Walsh, K. A., Titani, K., and Krebs, E. G. (1985) J. 
Biol. Chem. 260 , 1 1 2 7 5 -1 1 2 8 5 ), with a K, of 3.2 ± 
2.1 mm. Inhibition was competitive with respect to the 
peptide substrate Lys-Lys-Arg-Ala-Ala5-Arg-Ala- 
Thr-Ser-Asn10-Val-Phe-Ala and was of the noncom­
petitive linear mixed type with respect to ATP. M5 
and homologues with a serine residue substituted at 
positions 9, 13, or 14 were phosphorylated with the 
following order of preference: M5(Ser9) > M5(Ser13) 
»  M5(Ser14) > M5. The order of preference observed 
agreed with that predicted by comparison of the se­
quence of these peptides with the phosphorylation sites 
of myosin P-light chains. Both inhibition of C35 by M5 
and phosphorylation of M5 and its serine-substituted  
homologues were severely curtailed by the addition of 
a stoichiometric excess of CaM over peptide. Thus, 
synthetic peptides modeled after the CaM-binding do­
main of skeletal muscle myosin light chain kinase can 
function as calmodulin-regulated active site-directed  
inhibitors of the enzyme.
Many of the effects of the intracellular second messenger 
Ca2+ are mediated by the Ca2+-binding protein calmodulin 
(CaM).1 Upon binding Ca2+, CaM is transformed (9, 20) into
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a species capable of binding to and subsequently stimulating 
or activating a wide variety of enzymes including calcineurin, 
phosphorylase kinase, NAD kinase, multifunctional CaM ki­
nase II, CaM-dependent phosphodiesterases, CaM-regulated 
Ca2+-ATPases, CaM-sensitive adenylate cyclase, and the 
myosin light chain kinases (for reviews see Refs. 5, 16, 22, 
and 23). Although numerous CaM-modulated enzymes have 
been identified, the mechanism (s) by which CaM activates its 
targets has yet to be elucidated.
One of the best characterized of the CaM-modulated en­
zymes is skeletal muscle myosin light chain kinase (MLCK) 
(for reviews see Refs. 14 and 33). MLCK catalyzes the transfer 
of the 7 -phosphoryl group of ATP to a specific serine residue 
in myosin P-light chains. Its activity is completely CaM- 
dependent. As isolated from rabbit skeletal muscle, the en­
zyme is a monomer of 603 amino acids (35). Its hydrodynamic 
(24, 25) and catalytic (10, 26) properties have been studied in 
detail, and its complete amino acid sequence has recently been 
determined (34, 35). Partial proteolytic digestion of MLCK 
has provided evidence for division of the enzyme into func­
tional domains. Mayr and Heilmeyer (24, 25) were able to 
cleave MLCK into roughly two halves using protease activity 
endogenous to their preparations. One half was an asymmetric 
rodlike “tail” which was catalytically inactive. This fragment 
was hypothesized, by virtue of its shape and composition, to 
function in the binding of MLCK to myofilaments. The 
globular “head” fragment retained both catalytic activity and 
the ability to bind CaM. Using exogenous proteases such as 
trypsin and chymotrypsin, Edelman et al. (7) isolated and 
characterized similar CaM-dependent “head” fragments of 
MLCK. One of these, a chymotryptic fragment called C37,2 
was comprised of the C-terminal ~347 amino acids of MLCK 
(34). Upon further incubation with chymotrypsin, a slightly 
smaller proteolytic fragment, C35, was produced whose activ­
ity was completely CaM-independent and which failed to bind 
CaM immobilized onto a solid support (7). Since the sole 
common structural difference between the CaM-independent 
fragment C35 and the CaM-dependent ones produced by 
proteolytic digestion was the removal of 19 amino acids from 
the C terminus of the former (relative to the native protein) 
as opposed to a maximum of 8 or 9 from the latter, it was 
suggested that the CaM-binding domain resided in this region 
of MLCK (7). This was confirmed by Blumenthal et al. (2), 
who observed that a cyanogen bromide digest of MLCK 
contained only a single peptide capable of binding CaM with 
high affinity. This peptide, designated M13, was comprised of
2 The chymotryptic fragments C35, C36, and C37 were previously 
referred to as C/335, C/336, and C/337, respectively (7). The M, values 
implied by this terminology were based on polyacrylamide gel electro­

























the extreme C-terminal 27 amino acids of MLCK. Since M13 
bound CaM with the same high affinity (Kd S 1 nM ) and 1:1 
stoichiometry as does native MLCK (2, 18), it was concluded 
that this peptide contained within it the CaM-binding region 
of the enzyme. Additional studies with synthetic peptides 
have further localized the essential determinants of high 
affinity CaM binding to a sequence of 17 amino acids corre­
sponding to those occupying positions 577-593 in the enzyme 
d7, 35).
Comparison of the sequence of the CaM-binding domain of 
MLCK with the sequences of the phosphorylation sites of 
myosin P-light chains (28, 29) reveals significant similarities 
between them, especially with respect to the number and 
distribution of basic amino acid residues (Fig. 1, A and B). 
These basic residues are important determinants of the sub­
strate specificity of MLCK (12, 26), suggesting that such a 
substrate-like sequence might possess the ability to bind to 
the active site of the enzyme. If so, it would be expected to 
inhibit catalysis by blocking the access of substrates, specifi­
cally myosin P-light chains. Furthermore, it could be visual­
ized that CaM activation of MLCK would proceed via the 
removal of this “autoinhibitor” sequence from the active site 
as a result of its binding to CaM (Fig. 2). Upon dissociation 
of CaM in response to falling Ca2+ levels, this bifunctional 
autoinhibitor domain would be free once again to bind the 
enzyme’s active site and inhibit catalysis. The effectiveness 
of such inhibition would be greatly augumented by the inhib­
itor’s high local concentration, a consequence of its covalent 
attachment. Irreversible activation of MLCK by limited pro­
teolysis would be explained by the removal of the autoinhib­
itor sequence from the active site by its covalent cleavage 
from the enzyme, rather than via CaM binding.
In this study, we have utilized synthetic peptides modeled 
after the CaM-binding domain of MLCK to test some of the 
predictions of the autoinhibitor hypothesis.
EXPERIMENTAL PROCEDURES
Materials—Purchased materials included CM-Trisacryl ion-ex­
change resin (LKB-Produkter AB, Bromma, Sweden), phosphoric 
acid and high pressure liquid chromatography grade ammonium ace­
tate (J. T. Baker Chemical Co.), P81 ion-exchange paper (Whatman 
Ltd., Maidestone, England), Triton X-100 (Sigma), and Aquamix 
liquid scintillation mixture (Westchem, San Diego, CA). All other 
materials are from previously listed sources (X, 2, 7).
Proteins and Enzymes—The CaM-independent chymotryptic frag­
ment of rabbit skeletal muscle MLCK, C35, was prepared as described 
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Fig. 1. Sequence comparison between M5 and the phospho­
rylation sites on myosin P-light chains from skeletal and 
smooth muscle, and between M5 and MLC peptide. The se­
quence of the MLCK CaM-binding site peptide M5 is shown com­
pared with that of the phosphorylation site of rabbit skeletal muscle 
myosin P-light chain (Panel A, Ref. 29), the phosphorylation site of 
chicken smooth muscle myosin P-light chain (Panel B, Ref. 28), or 
MLC substrate peptide (Panel C, Ref. 12). Sequences were aligned so 
as to maximize both sequence identity and similarity in the distri­
bution of positively charged amino acid residues. Boxes indicate 
regions of similar charge or sequence identity. The phosphorylated 
serine of the various substrates is designated by an asterisk (*). The 
dashes (-) indicate areas where sequences were shifted in order to 
maximize similarity. The abbreviations of G-NHi and MLC stand for 
glycyl amide and myosin P-light chain, respectively.
MLCK- CaM  
( ac t i ve )
Fig. 2. The autoinhibitor hypothesis for the CaM-mediated 
activation of skeletal MLCK. The hatched circles correspond to 
the amino-terminal rodlike tail domain of MLCK. The open circles 
represent the catalytic domain, and the darkened circles represent the 
CaM-binding/autoinhibitor domain. The large circle with CaM in the 
center represents calmodulin.
described by Charbonneau et al. (4). Protein concentrations were 
determined by the method of Bradford (3), with the exception of 
CaM, which was determined by UV adsorption at 277 nm using an 
extinction coefficient of 3300 M-1 cm" 1 (15).
Peptides—Synthetic peptides were prepared by the Chemical Syn­
thesis Facility of the Howard Hughes Medical Institute at the Uni­
versity of Washington, Seattle. Syntheses were performed using an 
Applied Biosystems automated solid phase peptide synthesizer with 
subsequent cleavage by hydrofluoric acid (1). Peptides were then 
purified by ion-exchange chromatography. Crude peptide, 50-200 
/umol, was dissolved in a minimum volume of 0.2 M ammonium 
acetate, pH 7.0, and loaded onto a 1 x 20-cm column of CM-Trisacryl 
equilibrated in the same buffer. After washing with 2 column volumes 
of buffer, the column was eluted with a linear gradient consisting of 
200 ml each of 0.2 M ammonium acetate and 1.2 M ammonium acetate, 
both pH 7.0. Fractions, 2-4 ml each, were collected and peptides 
detected by their UV absorption at 280 nm. Peak fractions were 
pooled and their amino acid composition determined. Peptides with 
the correct composition were then sequenced both to confirm their 
identity and to check for impurities, which appeared in the form of 
underlying sequences since capping was not employed in the sequence 
protocol. By this criteria all peptides used were at least 90% pure. 
For M5 and its homologues, the most common contaminant was a 
peptide lacking one of the two arginine residues located at positions
2 and 3. Amino acid analysis and peptide sequence analysis were 
performed as described by Takio et al. (34). Prior to use, peptides 
were lyophilized to remove the ammonium acetate and dissolved in 
50 mM MOPS, pH 7.0. Peptide concentrations were determined by 
amino acid analysis. In the case of M5 and related peptides, this was 
sometimes checked by measuring UV absorbance at 280 nm using an 
extinction coefficient of 5550 M-1 cm-1 (1).
.Assay of MLCK Activity—Activity was determined by measuring 
the time-dependent incorporation of [32P]phosphate from [7 -32P] ATP 
into the substrate peptide Lys-Lys-Arg-Ala-Ala-Arg-Ala-Thr-Ser- 
Asn-Val-Phe-Ala (MLC peptide),3 by a modification of the procedure 
of Kemp and Pearson (12). MLC peptide represents a consensus 
sequence of the important specificity determinants found in the 
phosphorylation sites of myosin P-light chains and as such is an
3 MLC peptide was used in place of myosin P-light chains because 
it was observed that when present above micromolar concentrations, 
M5 peptide bound to and sometimes formed precipitates with mixed 
myosin light chain preparations. This was presumably due to the 
presence of endogenous calmodulin in these preparations (1 ) and/or 
the binding of M5 to the myosin light chains themselves, which 
























excellent substrate for MLCK from smooth and skeletal muscle (12). 
Assays were performed at 25 °C in a volume of 32 pi containing 50 
mM MOPS (pH 7.0), 12.5 mM MgCl2, 1 mM dithiothreitol, 2 mM 
EGTA, 1 mg/ml bovine serum albumin, 1% (v/v) Triton X-100, 0.2 
^g/ml C35, and varying amounts of MLC peptide and [7 -32P]ATP 
(specific radioactivity, 4-18 X 10ls cpm/mol), as well as other com­
pounds as noted. The concentrations of MLC peptide and ATP are 
listed in the individual table and figure legends. To ensure that the 
incorporation of phosphate into MLC peptide was linear with time, 
aliquots (8 pi) were removed at three separate times from each assay. 
These were spotted onto 2 X  2-cm squares of P81 ion-exchange 
chromatography paper and immediately immersed in 150 mM H3P 0 4 
to quench the reaction. Unreacted ATP, inorganic phosphate, etc. 
were removed from the peptide, which adheres to the paper, by 
washing for periods of 30 min to 12 h in 5-8 changes (400 ml each) 
of 150 mM H3PO< (30). The paper squares were suspended in a wire 
basket in order to allow the wash mixture to be stirred without 
damage to the paper. The paper squares were then washed for 1 min 
in 95% ethanol, air-dried, and counted in 4 ml of scintillation mixture 
using a Beckman LS 3133P liquid scintillation spectrometer. All 
assays were performed in triplicate, with the exception of the phos­
phorylation of M5 and its homologues in Fig. 5 and 6, where n — 1. 
All rates were corrected using appropriate substrate and enzyme 
blanks. Analysis of kinetic data was performed using the graphics 
and linear regression line fitting program contained in Cricket Graph 
(Cricket Software, Philadelphia, PA) on a Macintosh Plus personal 
computer (Apple Computers, Cupertino, CA).
RESULTS
The MLCK CaM-binding domain peptide, M5, was tested 
for its inhibitory properties. M5 has the following sequence: 
Lys-Arg-Arg-Trp-Lys6-Lys-Asn-Phe-Ile-Ala10-Val-Ser-Ala- 
Ala-Asn,5-Arg-Phe-Gly-NH2. The first 17 amino acids of this 
peptide are identical to those found in positions 577-593 of 
rabbit skeletal muscle MLCK (35). The glycyl amide group 
was added in order to eliminate the negative charge of the 
terminal carboxyl group, as no such charge is present at this 
position in the native protein. M5 binds CaM with the same 
high affinity (Kd S 1 nM ) as does the somewhat longer peptide 
M13 (2) and MLCK itself (27).
The inhibitory properties of M5 were examined using the 
CaM-independent chymotryptic fragment of MLCK, C35. 
This form of the enzyme was used, rather than native MLCK, 
for two reasons. First, we wished to examine the ability of M5 
to inhibit catalysis by MLCK independent of the peptide’s 
ability to inhibit CaM activation of the enzyme (2). Second, 
we wished to compare the inhibitory properties of both the 
free and the CaM-bound forms of M5. Since these experi­
ments required a CaM-independent source of MLCK activity, 
C35 was selected. The C35 preparations possess a disadvan­
tage in having a specific activity only about 5% that of native 
MLCK (7). However, the Km values of the chymotryptic 
fragment and the intact enzyme for rabbit skeletal muscle 
myosin light chains and ATP were almost the same (11.9 ± 
0.9 nM (n = 5) and 284 ± 59 pM (n = 7) for C35 versus 10-20 
juM for MLCK (33), respectively). Therefore, we felt that C35 
represented a suitable catalytic analogue of MLCK.
Initial experiments revealed that inhibition of C35 was 
detectable using micromolar concentrations of M5. Double 
reciprocal analysis showed that this inhibition was competi­
tive with respect to MLC peptide (Fig. 3), but noncompetitive 
linear mixed type (32) with respect to ATP (Fig. 4). Secondary 
plots of the data also indicated that the inhibition was com­
petitive in nature. Dixon plots displayed evidence of intersec­
tion in the fourth quadrant (Fig. 5, top), and replots of the 
slope of these plots as a function the 1 /MLC peptide were 
linear and intersected the origin (Fig. 5, bottom) as predicted 
for competitive inhibition. Other secondary plots graphing 
the slope or apparent Km generated from the double reciprocal 





Fig. 3. Inhibition of C35 by M5: MLC peptide as variable 
substrate. Activity was assayed as described under “Experimental 
Procedures” in the presence of varying concentrations of both MLC 
peptide and M5. The concentration of ATP was held constant at 1.0 
mM. The concentrations of MLC peptide employed were 20, 25, 40, 
80, or 160 pM. The concentrations of M5 used were 0 pM (x), 4 pM 
(■), 8 pM (A), or 12 pM (□).
1/ATP (mM-1)
Fig. 4. Inhibition of C35 by M5: ATP as variable substrate.
Activity was assayed as described under “Experimental Procedures” 
in the presence of varying concentrations of both ATP and M5. The 
concentration of MLC peptide was held constant at 240 pM. The 
concentrations of ATP employed were 100, 125, 167, 250, or 500 pM. 
The concentrations of M5 used were 0 pM (x ), 8 pM (■), 16 pM (A), 
or 24 pM (□).
shown). These various replots all suggest that the inhibition 
was competitive and results from the formation of a simple 
1:1  complex possessing no residual catalytic activity. The Kt 
determined from the average of three experiments of the type 
represented in Fig. 3 and 5 was 3.2 ±  2.1 pM.
The effect of CaM binding on the ability of M5 to inhibit 
C35 is shown in Table I. Under conditions where 65-69% of 
C35 activity was inhibited by M5, addition of a 5-fold excess 
of CaM over peptide resulted in near complete abolition of 
the latter’s inhibitory potency. This effect was, however, 
found to be independent of Ca2+, suggesting that while Ca2+ 
is needed for the high affinity binding of M5 and related 
peptides (2), CaM retains a finite (estimated Kd §  10-5 m ) 
affinity for them in the absence of Ca2+.
If M5 inhibited C35 by binding to the enzyme’s myosin P­


























Ca2+ EGTA CaM M5
%
— + — - 100 ±  3C
- + - + 31 ± 2
_ + + — 100 ± 3
- + + + 100 + 3
+ _ _ — 100 ± 6
+ - - + 35 ±  2
+ _ + — 100 ± 3
+ - + + 92 ± 8
(Fig. 1). In the first, based upon optimizing similarity with 
myosin P-light chain from skeletal muscle sources (29), the 
phosphorylated serine in the light chain was positioned op­
posite Ala13 in M5, or in a less likely alignment, Ala14 (Fig. 
1A). The second, based on smooth muscle myosin light chains 
(28) and MLC peptide (12), placed the phosphorylated serine 
opposite lie9 (Fig. 1, B and C). Since skeletal muscle MLCK 
readily phosphorylates myosin P-light chains from both skel­
etal and smooth muscle sources, as well as MLC peptide, in 
vitro (33), homologues of M5 containing serine at position 9, 
13, or 14 were synthesized. These were tested, along with M5 
itself (which already has a serine at position 12), as substrates 
for C35. As can be seen in Fig. 6, all four peptides could be 
phosphorylated, with the apparent order of preference 
M5(Ser9) > M5(Ser13) »  M5(Seru) > M5. The specific activ-
1/MLC Peptide (mM-1)
F ig . 5. Secondary plots o f inhibition of C35 by M5: MLC 
peptide as variable substrate. Top, the data from Fig. 3 repre­
sented as a Dixon plot giving 1 /velocity as a function of M5 concen­
tration for the following concentrations of MLC peptide: 20 fiM (x), 
25 mm (A), 40 fiM (A), 80 /iU (■), and 160 fiM (□). Bottom., a secondary 
plot of the Dixon plot displaying the slope of the Dixon plot as a 
function of 1 /MLC peptide concentration.
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F ig . 6. Phosphorylation of M5 and serine-substituted hom­
ologues by C35. The incorporation of 32P into M5 and variants 
thereof was measured under essentially the same conditions described 
under “Experimental Procedures” for the assay of MLCK activity. 
Modifications included raising the total volume to 48 pi, increasing 
the C35 concentration to 21 Mg/ml, and substituting the peptides 
listed below for MLC peptide. The concentrations of peptides and 
ATP were 50 nM and 1.0 mM, respectively. The peptide variants 
employed included M5, which has a serine at position 12 (M5, X), as 
well as homologues with a serine substituted for the alanine present 
at either position 13 (M5(Ser13), A) or 14 (M5(Ser14), ■) or for the 
isoleucine at position 9 (M5(Ser9), □).
° Assays were performed as described under “Experimental Pro­
cedures” with the following modifications. Instead of 2 mM EGTA, 
one or more of the following were present at the concentrations given 
in parentheses: CaCl2 (0.5 mM), EGTA (2 mM), CaM (95 fiM), and/ 
or M5 (20 nM). The presence or absence of each is indicated above 
by use of a + or —, respectively. The concentrations of MLC peptide 
and ATP were 40 /xM and 1.0 mM, respectively.
‘ All values represent the mean of three determinations plus or 
minus standard error. The relative activity is defined as the ratio of 
the activity for each set of additions of Ca2+, EGTA, or CaM in the 
presence of M5 peptide to that in its absence.
c 100% relative activity corresponds to an actual rate of 0.69 pmol/ 
min.
priately constructed homologue should be phosphorylated by 
the enzyme in the presence of ATP. Comparison of the amino 
acid sequence of M5 with those of the phosphorylation sites 
of myosin P-light chains and synthetic peptide substrates 











F ig . 7. Effect o f CaM on the phosphorylation of a serine- 
substituted homologue of M5. The measurement of [32P]phosphate 
incorporation into peptide M5(Ser9) was performed as described in 
the legend of Fig. 6, except that the assay mixtures contained either 
0.5 mM CaCl2 (—CaM, ■) or 0.5 mM CaCl2 plus a slight stoichiometric 
excess, 53 jiM, of CaM (+CaM, □). At the indicated times aliquots, 6 
1^ of each, were removed and 32P incorporation into peptide deter­

























ity of C35 toward these peptides was quite low, nearly 1000­
fold lower than toward myosin P-light chains or MLC peptide. 
The Km of C35 for the most readily phosphorylated peptides, 
M5(Ser9) and M5(Ser13), was similar to those of good peptide 
and protein substrates, however, approximately 15-20 for 
each (data not shown).
The effect of CaM binding upon the properties of M5 and 
its homologues as substrates for C35 was also examined. As 
can be seen in Fig. 7, the addition of a small stoichiometric 
excess of CaM over peptide M5(Ser9) dramatically decreased 
its rate of phosphorylation. Similar decreases in rate were 
also observed using the other three peptides as substrate (data 
not shown).
DISCUSSION
M5, a synthetic peptide modeled after the CaM-binding 
domain of rabbit skeletal muscle MLCK, inhibited the CaM- 
independent chymotryptic fragment of the enzyme, C35, with 
a Ki of 3.2 ± 2.1 /xM. Based on the following criteria, this 
inhibition appears to result from the binding of M5 to the 
enzyme’s myosin P-light chain substrate binding site. First, 
inhibition was competitive with respect to MLC peptide, but 
was of the noncompetitive linear mixed type with respect to 
ATP. This pattern of inhibition matches that predicted from 
the kinetic mechanism of MLCK for an active site-directed 
inhibitor (10). Second, the K  for M5 peptide was similar in 
magnitude, and in fact lower than, the Km of C35 for skeletal 
muscle myosin P-light chains (12 jtM). Third, secondary plots 
describing the inhibition suggest that the inhibition was com­
petitive and resulted from the formation of a 1:1 M5-enzyme 
complex which possessed no residual catalytic activity. 
Fourth, M5 and homologues synthesized with serine substi­
tuted for either lie9, Ala13, or Ala14 (M5(Ser9), M5(Ser13), and 
M5(Ser14), respectively) were phosphorylated by C35 with the 
order of preference predicted by comparison of their sequences 
to those of peptide and protein substrates. The Km values 
estimated for the two most readily phosphorylated peptides, 
M5(Ser9) and M5(Ser13), were comparable to those for myosin 
P-light chains and similar in magnitude to the if, of M5. This 
suggests that M5 and its homologues were able to bind C35 
in a substrate-like manner and do so at concentrations similar 
to those at which M5 was inhibitory.
It should be noted that the specific activity of C35 toward 
M5 and its homologues was nearly 1000-fold lower than its 
specific activity toward myosin P-light chains or MLC pep­
tide. This is not entirely unexpected, since the properties 
which render a molecule an effective active site-directed in­
hibitor do not necessarily coincide with those which render it 
a good substrate. For example, a serine-substituted peptide 
modeled after the heat-stable inhibitor of cAMP-dependent 
protein kinase turned out to be a very poor substrate of the 
enzyme (31). Conversely, attempts to develop inhibitors of 
this same kinase based upon the sequence of the excellent 
peptide substrate Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) 
met with little success (8, 1 1 ).
The ability of CaM to block both the inhibition of C35 by 
M5 and the phosphorylation of M5 and related homologues 
indicates that these peptides have little or no binding affinity 
for the enzyme’s active site following their complexation by 
CaM. This is significant, since it provides a mechanism by 
which CaM could relieve autoinhibition and activate MLCK. 
The abolition of M5-enzyme interaction upon complexation 
of the peptide to CaM was presumably the result of the spatial 
rearrangement of important binding determinants in M5 as 
well as their physical masking. The former would occur upon 
the transition of the peptide from an extended conformation
lacking ordered secondary structure to an a-helical one upon 
binding CaM (17, 18). CaM binding produces a similar in­
crease in the a-helical content of MLCK and its CaM-de­
pendent “head” fragments (25), suggesting that the enzyme’s 
CaM-binding domain (upon which M5 was modeled) may 
undergo a similar conformation change.
The question arises as to whether the bifunctional nature 
of M5 represents a property unique to it and its homologues 
or was merely a consequence of similarities between the 
primary sequence requirements for CaM and MLCK substrate 
binding. Four lines of evidence suggest that M5 is uniquely 
adapted for its dual role. First, another potent CaM binding 
peptide, mastoparan (21), was an extremely poor inhibitor of 
C35.4 Second, the numerous studies performed on peptide 
substrates and competitive inhibitors of the myosin light 
chain kinases, such as MLC peptide, have failed to reveal any 
high affinity CaM antagonist ability endogenous to them (12, 
26). Third, partial proteolytic digestion of MLCK with chy- 
motrypsin produced an intermediate form between the CaM- 
dependent C37 and CaM-independent C35. This form, C36,2 
was still fully CaM-dependent but required much higher con­
centrations of CaM to become activated (7). This suggests 
that residues essential for the high affinity binding of CaM 
were removed without affecting those essential for inhibition 
of activity. Fourth, although both CaM binding and MLCK 
substrate binding require clusters of positively charged amino 
acids as their most obvious common structural determinant, 
the spatial requirements for the arrangement of these clusters 
probably differ greatly. Substrates and inhibitors of MLCK 
require a fairly strict spacing of basic residues within their 
linear sequence (12 , 26), presumably reflective of the adoption 
of an extended conformation when bound to the enzyme active 
site. CaM binding peptides require that their basic residues 
be distributed such that they all reside on one face of an 
amphipathic helix, the conformation which these peptides 
adopt upon binding to CaM (6). This three-dimensional ar­
rangement can be accommodated by a large number of distinct 
spacings within a peptide’s linear sequence, only some of 
which conform to those compatible with the specificity deter­
minants of the MLCK active site.
To summarize, the above results indicate that M5, a syn­
thetic peptide modeled after the CaM-binding domain of 
rabbit skeletal muscle MLCK, is a CaM-regulated competitive 
inhibitor of the active chymotryptic fragment of the enzyme, 
C35. Such behavior is consistent with the concept that the 
CaM-binding domain of native MLCK functions as a CaM- 
regulated autoinhibitor of enzymatic activity (Fig. 2) and 
suggests that the functions of CaM binding and enzyme 
inhibition, therefore, reside in identical or highly overlapping, 
rather than discrete, domains as had previously been specu­
lated (7). However, although consistent with this mechanism, 
these results do not rule out alternative mechanisms such as 
a CaM-induced change in the structure of the MLCK active 
site itself or the CaM-induced movement of portions of the 
protein which might sterically block the active site. The final 
word on the relevance of the inhibitory properties of M5 to 
the mechanism of the CaM-regulated activation/inactivation 
of skeletal muscle MLCK must, therefore, await further in­
vestigation by x-ray crystallography and other means. How­
ever, several things are worthy of note. The first is that the 
autoinhibitor hypothesis requires that the CaM-binding do­
main of MLCK must be suitably positioned and possess 
sufficient conformational flexibility to swing into and out of 
the enzyme’s active site. The CaM-binding domain of MLCK 
is located at the extreme C terminus of the enzyme, a region























more likely to possess a high degree of flexibility than areas 
nearer the center of the polypeptide chain. Furthermore, 
circular dichroism and nuclear magnetic resonance data sug­
gest that M5 and related peptides adopt a flexible extended 
conformation in solution (17,18) and thus might be expected 
to do so in MLCK. Second, the proposed model is consistent 
with the observation that skeletal muscle MLCK possesses a 
catalytic core which expresses CaM-independent activity fol­
lowing the proteolytic removal of the enzyme’s CaM-binding 
domain (7). In this circumstance, activation would be attrib­
utable to the removal of the autoinhibitor from the active site 
by physical cleavage, rather than CaM binding. Partial pro­
teolysis of other CaM-regulated enzymes such as CaM-de­
pendent phosphodiesterase (19) and calcineurin (24) also 
results in the appearance of CaM-independent active forms 
of these enzymes. Thus, it is possible that other CaM-modu­
lated enzymes may possess a similar domain organization as 
skeletal muscle MLCK and may, therefore, be activated in a 
manner similar to that postulated here.
Perhaps the strongest support for the autoinhibitor hypoth­
esis appeared while this manuscript was in the late stages of 
preparation in a report detailing the CaM and substrate 
antagonist abilities of synthetic peptides toward the smooth 
muscle isozyme of MLCK (13). These synthetic peptides were 
modeled after portions of the putative CaM-binding domain 
of smooth muscle MLCK or, in one instance, a portion of the 
CaM-binding domain of the skeletal muscle isozyme (residues 
577-587 as opposed to residues 577-593 for M5). Many of 
these peptides were found to be potent inhibitors of the CaM 
activation of smooth muscle MLCK as well as competitive 
inhibitors of the activated enzyme with respect to myosin P ­
light chains. Although the ability of the smooth muscle MLCK 
peptides to inhibit the CaM activation of the enzyme could 
be overcome by the addition of excess CaM, their active site- 
directed inhibitory capabilities were not. Kemp et al. (13) 
postulated on the basis of these observations that the CaM- 
binding domain of smooth muscle MLCK was a bifunctional 
domain which bound to the active site in the absence of CaM 
as a “pseudosubstrate” and blocked enzymatic activity. Thus, 
synthetic peptides modeled after the CaM-binding domains 
of smooth and skeletal muscle MLCK exhibit similar inhibi­
tory properties toward their respective parent enzymes, and 
this has led to the postulation of similar autoinhibitor-type 
mechanisms for each. These parallels take on added signifi­
cance when one considers that the skeletal and smooth muscle 
isozymes of MLCK differ greatly enough in molecular weight, 
antigenic properties, and molecular architecture to be consid­
ered, in many ways, distinct CaM-regulated proteins (33).
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